Market News & Trends
Evonik Expands North American Contract Development & Manufacturing Capabilities for Advanced Injectables
Evonik recently announced a €35 million expansion of its contract development and manufacturing (CDMO) capabilities in North America to meet growing demand for controlled release injectable formulations. The expansion of the U.S. and Canadian facilities, which includes the installation of a new filling line, production facilities and analytical labs, will create more than 50 jobs.
Novacap to Expand its Pharmaceutical Offering in US With Major Acquisition
Novacap recently announced it has signed an agreement to acquire Boston-based PCI Synthesis, a leading US pharmaceutical contract development and manufacturing organization (CDMO), further reinforcing Novacap’s capabilities and offering for the pharmaceutical industry.
Epinephrine Nasal Spray in Development for Treatment of Anaphylaxis Shows Promise as Potential Alternative to Intramuscular Injection
INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that its investigational epinephrine nasal spray showed promise in an early clinical trial as a potential needle-free, non-invasive and easy-to-use alternative to intramuscular injection for the treatment of anaphylaxis.
Zealand Pharma Achieves Milestone in First Phase 3 Trial
Zealand Pharma A/S recently announced that the primary and key secondary objectives of the first multinational Phase 3 clinical trial of dasiglucagon for the treatment…
Saama Launches Deep Learning Intelligent Assistant (DaLIA) to Solve Clinical Development Pain Points
Saama Technologies, Inc. recently announced the launch of a unique set of Artificial Intelligence (AI) capabilities specifically designed to alleviate the planning, feasibility, and conduct…
Paratek Presents New Analysis From Combined Phase 3 Skin Infection Studies
Paratek Pharmaceuticals, Inc. recently presented a new analysis of combined data from the company’s two, pivotal Phase 3 clinical studies of omadacycline in acute bacterial…
Nutriband Signs LOI to Acquire Carmel Biosciences
Nutriband Inc. recently announce it has signed a Letter of Intent to acquire 100% of Carmel Biosciences, a pharmaceutical company that addresses critical needs in…
Nkarta Therapeutics Announces Exclusive License to Natural Killer Cell Technology
Nkarta Therapeutics recently announced it has entered into a worldwide exclusive license agreement for proprietary Natural Killer cell engineering technology jointly owned by the National…
Avalon GloboCare Forms Joint Venture With Jiangsu Unicorn to Establish Provincial Network of Translational Cellular Therapy & Bio-Banking Programs
Avalon GloboCare Corp. recently announced it has formed a joint venture with Jiangsu Unicorn Biological Technology Co. Ltd, which brings extensive medical resources in Jiangsu…
Pfanstiehl Launched New cGMP-Produced Galactose for Cell Culture Media Optimization & Production of Therapeutic Recombinant Glycoproteins
As part of Pfanstiehl’s continual commitment to producing the industry’s highest purity, lowest endotoxin and lowest metals (HPLE-LM) for bioprocessing components, two new D-Galactose products have been launched.
Endocyte Announces Enrollment of First Patient in Phase 3 VISION Trial
Endocyte, Inc. recently announced the enrollment of the first patient in its global phase 3 VISION trial of 177Lu-PSMA-617 in prostate cancer by Dr. Luke…
Stemline Therapeutics Announces Positive Data Presentations on SL-701 & SL-801 at ASCO
Stemline Therapeutics, Inc. recently announced that positive data from the SL-701 and SL-801 clinical trials were presented at the 2018 American Society of Clinical Oncology…
IONTAS Signs Collaboration Agreement With LG Chem, Ltd.
IONTAS Limited recently announced it has signed a collaboration agreement with Korean-based LG Chem, Ltd. for the discovery of therapeutic antibodies targeting undisclosed targets for…
TESARO Announces Collaboration to Evaluate ZEJULA in Combination With Anti-PD-L1 Cancer Immunotherapy & MEK Inhibitor
TESARO, Inc. recently announced it has entered into a clinical collaboration with Genentech, a member of the Roche Group, to evaluate the combination of the…
Aphios Granted US Patent for Improved Delivery of Targeted siRNA Using Nanotechnology
Aphios Corporation recently announced it has been granted United States Patent No. 9,981,238 titled Apparatus and Methods for Making Nanosomes Loaded with Nucleic Acids. The…
Lonza & Innosieve Diagnostics Announce Exclusive Distribution Agreement
Lonza Pharma & Biotech and Innosieve Diagnostics recently announced an exclusive distribution agreement for rapid bioburden testing technology. This agreement expands Lonza’s extensive offering of…
FUJIFILM Cellular Dynamics Licenses University of California – Irvine’s Technologies
FUJIFILM Cellular Dynamics, Inc. (FCDI) recently announced it has entered into an exclusive patent license agreement with the University of California – Irvine (UCI) through its offices at UCI Applied Innovation to license and commercialize UCI’s technologies for derivation of microglia in the commercial research field and also a non-exclusive patent license agreement to commercialize microglia media formulation.
eFFECTOR Initiates Dosing of eFT508 in Phase 2 Expansion of Clinical Trial in Aggressive Form of Non-Hodgkin’s Lymphoma
eFFECTOR Therapeutics, Inc. recently announced that it has dosed the first patient in the Phase 2 expansion portion of its monotherapy trial of eFT508, the company’s oral, small molecule inhibitor of MNK1/2, for the treatment of relapsed, refractory non-germinal center B cell (non-GCB) diffuse large B cell lymphoma (DLBCL).
Axovant Licenses Investigational Gene Therapy for Parkinson’s Disease From Oxford BioMedica; Announces Key Leadership Team Addition
Axovant Sciences recently announced that it has licensed the exclusive worldwide rights to develop and commercialize OXB-102, now AXO-Lenti-PD, from Oxford BioMedica. AXO-Lenti-PD is an investigational gene therapy for Parkinson’s disease that delivers three genes encoding a critical set of enzymes required for dopamine synthesis in the brain.
Immunomodulation Therapies Designed to Suppress Tumors & Fight Infection
Immunomodulation Inc. recently outlined its upcoming plans to advance its investigational product candidate, IMM-010, following consistent positive data from preclinical studies.
